158 related articles for article (PubMed ID: 19904520)
1. Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.
Sumi M; Ichikawa N; Nasu K; Shimizu I; Ueki T; Ueno M; Kobayashi H
Int J Hematol; 2009 Dec; 90(5):643-647. PubMed ID: 19904520
[TBL] [Abstract][Full Text] [Related]
2. Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation.
Ando T; Mitani N; Matsunaga K; Nakazora T; Gondo T; Yujiri T; Tanizawa Y
Tohoku J Exp Med; 2010 Feb; 220(2):121-6. PubMed ID: 20139663
[TBL] [Abstract][Full Text] [Related]
3. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
5. Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.
Koren-Michowitz M; Maayan H; Apel A; Shem-Tov N; Yerushalmi R; Volchek Y; Avigdor A; Shimoni A; Nagler A
Ann Hematol; 2015 Mar; 94(3):375-8. PubMed ID: 25307457
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
[TBL] [Abstract][Full Text] [Related]
7. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
Wadleigh M; Richardson PG; Zahrieh D; Lee SJ; Cutler C; Ho V; Alyea EP; Antin JH; Stone RM; Soiffer RJ; DeAngelo DJ
Blood; 2003 Sep; 102(5):1578-82. PubMed ID: 12738663
[TBL] [Abstract][Full Text] [Related]
8. Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation.
Chevallier P; Prebet T; Turlure P; Hunault M; Vigouroux S; Harousseau JL; Blaise D; Ifrah N; Milpied N; Mohty M
Bone Marrow Transplant; 2010 Jan; 45(1):165-70. PubMed ID: 19584826
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.
de Lima M; Champlin RE; Thall PF; Wang X; Martin TG; Cook JD; McCormick G; Qazilbash M; Kebriaei P; Couriel D; Shpall EJ; Khouri I; Anderlini P; Hosing C; Chan KW; Andersson BS; Patah PA; Caldera Z; Jabbour E; Giralt S
Leukemia; 2008 Feb; 22(2):258-64. PubMed ID: 17989720
[TBL] [Abstract][Full Text] [Related]
10. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
[TBL] [Abstract][Full Text] [Related]
11. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
12. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.
Leopold LH; Berger MS; Feingold J
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S29-34. PubMed ID: 11970768
[TBL] [Abstract][Full Text] [Related]
13. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis.
Zwaan CM; Reinhardt D; Corbacioglu S; van Wering ER; Bökkerink JP; Tissing WJ; Samuelsson U; Feingold J; Creutzig U; Kaspers GJ
Blood; 2003 May; 101(10):3868-71. PubMed ID: 12543868
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
[TBL] [Abstract][Full Text] [Related]
15. Successful repeated treatment of acute myeloid leukemia in early relapse with gemtuzumab ozogamicin alone.
Tsunemine H; Akasaka H; Sakane EI; Ito K; Kodaka T; Takahashi T
Int J Hematol; 2014 Feb; 99(2):193-7. PubMed ID: 24293280
[TBL] [Abstract][Full Text] [Related]
16. Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia.
Yamauchi T; Mori Y; Miyamoto T; Kamezaki K; Aoki T; Yamamoto A; Takenaka K; Iwasaki H; Harada N; Nagafuji K; Teshima T; Akashi K
Int J Hematol; 2009 Oct; 90(3):416-420. PubMed ID: 19697098
[TBL] [Abstract][Full Text] [Related]
17. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Ho VT; Martin AS; Pérez WS; Steinert P; Zhang MJ; Chirnomas D; Hoang CJ; Loberiza FR; Saber W
Biol Blood Marrow Transplant; 2020 May; 26(5):884-892. PubMed ID: 31891815
[TBL] [Abstract][Full Text] [Related]
18. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
Molnár I; Powell BL
Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
[TBL] [Abstract][Full Text] [Related]
19. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
20. Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.
Debureaux PE; Labopin M; Mamez AC; Lapusan S; Isnard F; Adaeva R; Bonnin A; Hirsch P; Delhommeau F; Battipaglia G; Duléry R; Malard F; Vekhoff A; Mohty M; Legrand O; Brissot E
Bone Marrow Transplant; 2020 Feb; 55(2):452-460. PubMed ID: 31554931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]